Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Centre, Retrospective Study Assessing the Long Term Outcome Post to Discontinuation of Anti-PD-1 Therapy and Efficacy of Retreatment with Anti-PD-1 Therapy With or Without Ipilimumab in Patients With Relapsing Unresectable Stage III/IV Melanoma

Next Previous
Search
Trial Profile

A Single Centre, Retrospective Study Assessing the Long Term Outcome Post to Discontinuation of Anti-PD-1 Therapy and Efficacy of Retreatment with Anti-PD-1 Therapy With or Without Ipilimumab in Patients With Relapsing Unresectable Stage III/IV Melanoma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma; Skin cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Jun 2021 Results (N=151), of a 5 year long term analysis in the melanoma patients who survived at least five years following their first dose of immune checkpoint blockade, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 20 Feb 2020 New trial record
    • 13 Feb 2020 Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top